Revive Therapeutics Ltd.
RVV
CNSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 30.42% | 39.40% | 8.03% | -1.87% | 1.87% |
| Depreciation & Amortization | -50.00% | -25.00% | 0.00% | 0.00% | 0.00% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -15.64% | -18.75% | -42.18% | -59.31% | -72.85% |
| Operating Income | 15.64% | 18.75% | 42.18% | 59.31% | 72.85% |
| Income Before Tax | -22.06% | -12.06% | 12.39% | 48.10% | 65.99% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -22.06% | -12.06% | 12.39% | 48.10% | 65.99% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -22.06% | -12.06% | 12.39% | 48.10% | 65.99% |
| EBIT | 15.64% | 18.75% | 42.18% | 59.31% | 72.85% |
| EBITDA | 15.63% | 18.75% | 42.19% | 59.31% | 72.85% |
| EPS Basic | 0.00% | 7.89% | 27.59% | 52.69% | 67.47% |
| Normalized Basic EPS | 25.53% | 32.20% | 49.37% | 63.79% | 74.18% |
| EPS Diluted | 0.00% | 7.89% | 27.59% | 52.69% | 67.47% |
| Normalized Diluted EPS | 25.53% | 32.20% | 49.37% | 63.79% | 74.18% |
| Average Basic Shares Outstanding | 20.26% | 18.67% | 17.04% | 9.39% | 5.92% |
| Average Diluted Shares Outstanding | 20.26% | 18.67% | 17.04% | 9.39% | 5.92% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |